United States Patent 10,231,981: Critical Claim Map and US Patent Landscape for Subcutaneous Anti-IL-6R in Juvenile Idiopathic Arthritis
US Patent 10,231,981 is built around a narrow but strategically valuable clinical-rights construct: subcutaneous anti-IL-6R therapy for juvenile idiopathic arthritis (JIA), using a fixed 162 mg dose schedule with explicit regimen timing (weekly, every two weeks, or every three weeks) and an IL-6R antibody sequence anchor for the anti-IL-6R version. The claims then mirror the same treatment architecture for tocilizumab (an anti-IL-6R antibody), including identical fixed-dose timing rules keyed to patient weight thresholds (≥30 kg vs <30 kg) and JIA subtypes (sJIA and pcJIA).
What do the claims actually cover?
How is the anti-IL-6R antibody claimed?
Independent claim 1 is the fulcrum. It covers a treatment method for JIA using a subcutaneous anti-IL-6R antibody with four hard limitations:
- Indication: “treating juvenile idiopathic arthritis (JIA) in a patient”
- Administration route: subcutaneous (explicitly)
- Dose form: fixed dose of 162 mg per dose
- Regimen timing: every week, every two weeks, or every three weeks
- Molecular identity: the antibody “comprises the light chain and heavy chain amino acid sequences of SEQ ID NOs: 1 and 2, respectively”
Claim set 2 through 7 narrows the JIA subtype and ties dosing interval to weight:
- sJIA: claim 2; time pattern in claims 3–4 is weight-conditioned
- pcJIA: claim 5; time pattern in claims 6–7 is weight-conditioned
Weight-conditioned interval rules
- For ≥ 30 kg: weekly (claim 3) for sJIA; every two weeks (claim 6) for pcJIA
- For < 30 kg: every two weeks (claim 4) for sJIA; every three weeks (claim 7) for pcJIA
How is tocilizumab claimed?
Independent claim 8 parallels claim 1 but substitutes the molecular limitation with a named biologic:
- Subcutaneous tocilizumab
- Fixed dose: 162 mg per dose
- Regimen timing: every week, every two weeks, or every three weeks
Claims 9–14 mirror the subtype and weight-conditioned interval structure:
- sJIA: claim 9; intervals in claims 10–11
- ≥30 kg: weekly (claim 10)
- <30 kg: every two weeks (claim 11)
- pcJIA: claim 12; intervals in claims 13–14
- ≥30 kg: every two weeks (claim 13)
- <30 kg: every three weeks (claim 14)
Claim coverage summary table (US10,231,981)
| Claim |
Patient population |
Molecular limitation |
Route |
Dose |
Interval menu |
Weight tie-in |
| 1 |
JIA (all) |
anti-IL-6R antibody with SEQ ID NOs 1/2 |
SC |
162 mg |
wk, q2wk, q3wk |
No |
| 2 |
sJIA |
Same as claim 1 |
SC |
162 mg |
wk, q2wk, q3wk |
Yes via claims 3–4 |
| 3 |
sJIA |
Same |
SC |
162 mg |
weekly |
≥30 kg |
| 4 |
sJIA |
Same |
SC |
162 mg |
q2wk |
<30 kg |
| 5 |
pcJIA |
Same |
SC |
162 mg |
wk, q2wk, q3wk |
Yes via claims 6–7 |
| 6 |
pcJIA |
Same |
SC |
162 mg |
q2wk |
≥30 kg |
| 7 |
pcJIA |
Same |
SC |
162 mg |
q3wk |
<30 kg |
| 8 |
JIA (all) |
tocilizumab |
SC |
162 mg |
wk, q2wk, q3wk |
No |
| 9 |
sJIA |
tocilizumab |
SC |
162 mg |
wk, q2wk, q3wk |
Yes via claims 10–11 |
| 10 |
sJIA |
tocilizumab |
SC |
162 mg |
weekly |
≥30 kg |
| 11 |
sJIA |
tocilizumab |
SC |
162 mg |
q2wk |
<30 kg |
| 12 |
pcJIA |
tocilizumab |
SC |
162 mg |
wk, q2wk, q3wk |
Yes via claims 13–14 |
| 13 |
pcJIA |
tocilizumab |
SC |
162 mg |
q2wk |
≥30 kg |
| 14 |
pcJIA |
tocilizumab |
SC |
162 mg |
q3wk |
<30 kg |
What is the critical legal and commercial thesis?
Is this a broad “anti-IL-6R for JIA” patent or a narrow regimen-and-sequence patent?
It is primarily a regimen-and-sequence patent, not a broad target patent.
- The indication is limited to juvenile idiopathic arthritis and then further sliced into sJIA and pcJIA.
- The route is fixed to subcutaneous.
- The dose is fixed to 162 mg per dose (not weight-based mg/kg).
- The interval is fixed to a limited menu (weekly, q2wk, q3wk).
- In claim 1, the molecule identity is fixed by SEQ ID NOs 1 and 2 (heavy and light chains).
This structure matters because it limits design-around options: replacing the route (IV), changing the dose amount, changing the interval logic, or altering the antibody sequence profile can avoid literal coverage, depending on the exact prosecution history and infringement posture. But in practice, payor and label-driven dosing tends to track exactly what the patent claims.
Claim-by-claim criticality: where infringement and validity stress points likely concentrate
Where does claim 1 create the biggest moat?
Claim 1 locks in two layers:
- Biology layer: specific SEQ ID NO sequences for heavy and light chains
- Protocol layer: fixed 162 mg SC dosing at wk/q2wk/q3wk intervals
This combination reduces the risk of the claim reading on off-target antibodies that may still bind IL-6R, because the sequence requirement narrows identity.
What is the vulnerability: timing ambiguity vs explicit weight gating?
The claims include both an “interval menu” (wk, q2wk, q3wk) and a weight-based mapping in dependent claims.
- In dependent claims 3–4 and 6–7, the weight threshold is explicit and the interval is deterministic:
- sJIA: ≥30 kg weekly; <30 kg q2wk
- pcJIA: ≥30 kg q2wk; <30 kg q3wk
- That determinism is strong for enforcement. If actual prescribed practice follows label-based weight gating, these claims are positioned to capture routine clinical use.
How do the tocilizumab claims broaden or simplify enforcement?
Claims 8–14 use the named biologic tocilizumab, which can be easier to litigate than sequence matching. For generic/biosimilar strategy, named-product claims often reduce molecular argument space.
At the same time, the regimen constraints (SC route, 162 mg fixed dose, interval mapping) still make the claims execution-specific.
Relationship to standard-of-care labeling and practical dosing
Why the “162 mg fixed dose + SC + interval mapping” is commercially targeted
In juvenile disease management, dosing schedules are typically designed to preserve exposure while reducing injection burden. A fixed-dose 162 mg SC regimen with interval changes based on a patient weight cut (30 kg) is the type of label-driven protocol that:
- creates predictable prescribing patterns,
- reduces off-label variation (especially for sJIA and pcJIA),
- increases the probability of “method-of-treatment” infringement tied to routine administration.
The patent’s claim architecture aligns with that pattern.
US patent landscape: what can be said from the claim set itself
What does the claim set imply about surrounding IP structure?
Even without reviewing the prosecution file, the claim style signals a likely landscape shape:
- One cluster focused on SC administration of anti-IL-6R in JIA
- Separate claim tracks for:
- molecular composition identity (SEQ ID NOs for anti-IL-6R antibody),
- named drug identity (tocilizumab),
- indication subtypes (sJIA vs pcJIA),
- dose regimen rules (fixed 162 mg; interval selection; weight gating)
This tends to co-exist with other US patent families in the same ecosystem, typically split among:
- composition-of-matter (biologic itself),
- formulation and delivery device (SC product),
- dosing regimen or method-of-use (treatment method).
Because this patent is expressly a method-of-treatment patent with explicit dosing instructions, its enforcement leverage generally depends on commercial and clinical utilization aligning with the claimed protocol.
Critical assessment: strength, enforceability leverage, and design-around pressure
What makes this patent enforceable in practice?
- Method claim anchored to a standard clinical action: administering a drug to treat JIA.
- Route explicitly SC.
- Dose and schedule are explicit, not implied.
- Weight threshold is explicit in dependent claims.
- Two coverage tracks exist:
- sequence-defined anti-IL-6R antibody (claim 1)
- named tocilizumab (claim 8)
- Two main JIA categories are included, capturing major prescriber use-cases.
Where design-around pressure can exist
Literal design-around is possible if a competitor changes any of the following:
- SC route (use IV),
- fixed dose amount (change from 162 mg),
- dosing interval mapping (for example, different weight threshold or different schedule),
- molecular identity (for anti-IL-6R claim 1, change outside SEQ ID NO scope),
- treat a different patient subset or use different diagnostic labeling thresholds (though that is typically harder).
However, the tocilizumab claims (8–14) reduce the “molecular design-around” option; only regimen changes remain.
Key Takeaways
- US 10,231,981 is a regimen-and-identity method-of-treatment patent for subcutaneous anti-IL-6R (including tocilizumab) in JIA, centered on a fixed 162 mg dose with weekly / q2wk / q3wk intervals.
- Dependent claims convert interval selection into a deterministic weight-based rule at 30 kg, with different mapping for sJIA vs pcJIA.
- Enforcement leverage is high when real-world prescribing matches the claimed protocol and when the product is tocilizumab or an antibody that meets the SEQ ID NO requirement in claim 1.
- Design-around is most feasible by changing route, dose amount, or the weight-to-interval mapping, since the tocilizumab track is molecularly direct.
FAQs
1) Does the patent cover both sJIA and pcJIA?
Yes. sJIA is covered in claims 2–4 and pcJIA in claims 5–7 (anti-IL-6R) and claims 9–11 and 12–14 (tocilizumab).
2) What is the fixed dose amount claimed?
The fixed dose is 162 mg per dose (claims 1 and 8 and all dependent protocol claims).
3) Is the dosing interval weight-dependent?
Yes in the dependent claims:
- sJIA: ≥30 kg = weekly, <30 kg = every two weeks
- pcJIA: ≥30 kg = every two weeks, <30 kg = every three weeks
4) How does the patent define the antibody in the anti-IL-6R claims?
Claim 1 requires the antibody to “comprise” light chain and heavy chain amino acid sequences of SEQ ID NOs: 1 and 2, respectively.
5) Can a competitor avoid the patent by switching to another IL-6R antibody?
For claim 8–14, molecular changes do not help because they are limited to tocilizumab. For claim 1–7, a different anti-IL-6R antibody may avoid coverage if it does not meet the SEQ ID NO sequence limitation, but regimen constraints still apply.
References
- United States Patent 10,231,981. Claims 1-14 as provided in the prompt.
